Form D - Notice of Exempt Offering of Securities:
SEC Accession No. 0001772230-19-000001
Filing Date
2019-03-29
Accepted
2019-03-28 18:50:32
Documents
1
Effectiveness Date
2019-03-29
Items
Item 06b:
Item 3C: Investment Company Act Section 3(c)
Item 3C.7: Section 3(c)(7)

Document Format Files

Seq Description Document Type Size
1 primary_doc.html D  
1 primary_doc.xml D 12414
  Complete submission text file 0001772230-19-000001.txt   13657
Mailing Address LETTERMAN DIGITAL ARTS CENTER ONE LETTERMAN DRIVE, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address LETTERMAN DIGITAL ARTS CENTER ONE LETTERMAN DRIVE, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Biopharma Investments II, L.P. (Filer) CIK: 0001772230 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: D | Act: 33 | File No.: 021-335974 | Film No.: 19713390